Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jan 30:2014:bcr2013202861.
doi: 10.1136/bcr-2013-202861.

Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy

Jason Adhikaree  1 , Yvette Newby, Santhanam Sundar
Affiliations
Case Reports

Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy

Jason Adhikaree et al. BMJ Case Rep. .

Abstract

Denosumab, a fully humanised monoclonal antibody, is licensed for treatment of postmenopausal osteoporosis, hormone ablation-induced bone loss and for prevention of skeleton-related events in patients with bone metastases from solid tumours. In pivotal phase 3 randomised trials, denosumab caused profound hypocalcaemia in patients with normocalcaemia despite oral calcium and vitamin D supplementation. This significant hypocalcaemic effect can be exploited to treat hypercalcaemia of malignancy (HCM). Recent reports from the USA suggest that denosumab is an effective treatment of HCM. According to our knowledge, we report the first two cases in UK with bisphosphonate refractory hypercalcaemia who responded to denosumab injections. Our first case gained 7 months of stabilisation of hypercalcaemia following prolonged admissions with life-threatening levels, while our second case achieved rapid normalisation of serum calcium levels for the first time in 14 months. We conclude that denosumab should be the treatment of choice for patients with bisphosphonate refractory hypercalcaemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of hypercalcaemia from paraneoplastic syndrome and bone metastasis.
Figure 2
Figure 2
Case 1: Adjusted calcium levels from diagnosis (day 1) until present day. Note blue arrows denote intravenous fluids±zoledronic acid. Green arrow indicates treatment with denosumab. Dashed red line shows upper limit of normal for adjusted serum calcium. Orange arrow denotes where patient received calcitonin 200 units subcutaneous injection as inpatient three times daily increased to four times daily, but stopped on starting denosumab.
Figure 3
Figure 3
Case 2: Adjusted calcium levels from diagnosis of relapse (day 1) until present day. Note blue arrows denote hospital admissions for intravenous fluids and zoledronic acid. Green arrow indicates treatment with denosumab. Dashed red line shows upper limit of normal for adjusted serum calcium.
See this image and copyright information in PMC

References

    1. National Cancer Institute: PDQ Hypercalcemia Bethesda, MD: National Cancer Institute; Date last modified 01/09/2013. [Internet]. [cited 28 Oct 2013]. http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/Heal...
    1. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–67 - PubMed
    1. Castellano D, Sepulveda JM, García-Escobar I, et al. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011;16:136–45 - PMC - PubMed
    1. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–55 - PMC - PubMed
    1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756–65 - PubMed

Publication types

MeSH terms

Supplementary concepts